Phosphodiesterase sequence variants may predispose to prostate cancer

Area of Science:

• Genetics
• Oncology
• Molecular Biology

Background:

• Prostate cancer (PCa) is a significant health concern.
• Phosphodiesterase (PDE) enzymes regulate cyclic nucleotide levels, implicated in various cellular processes.
• Dysregulation of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) signaling pathways is observed in cancers.

Purpose of the Study:

• To investigate the association between phosphodiesterase (PDE) gene mutations and prostate cancer (PCa).
• To explore the role of PDE variants in PCa predisposition and progression.
• To examine the relationship between PDE defects and the expression of CREB (cAMP response element-binding protein) and pCREB (phosphorylated CREB).

Main Methods:

• Sequencing of entire PDE coding sequences in 16 PCa biopsy samples.
• Confirmation of novel mutations using Sanger sequencing.
• Immunofluorescence analysis of PDE, CREB, and pCREB protein expression in normal and tumor tissues.
• Comparison of identified variants with the 1000 Genomes Project database.

Main Results:

• Three known PDE sequence variants were significantly more frequent in PCa patients.
• Four novel sequence variations were identified in PDE4B, PDE6C, PDE7B, and PDE10A genes.
• Novel variants in PDE10A and PDE4B were found exclusively in tumor tissue.
• Patients with PDE defects exhibited pCREB accumulation and an increased pCREB:CREB ratio.

Conclusions:

• PDE sequence variants may contribute to prostate cancer (PCa) predisposition and/or progression.
• Both germline and somatic mutations in PDE genes could be implicated.
• The observed pCREB accumulation suggests a downstream effect of PDE defects in PCa pathogenesis.